A New Therapeutic Principle in Anticoagulation
Why the study?
Despite anticoagulant advancements, bleeding concerns and managing thrombotic risks persist, driving the need for therapies that prevent thrombosis while minimizing bleeding.
Do factor XI inhibitors prevent thrombosis while minimizing bleeding risks in patients at risk of thrombotic events?
Design
Review article
Authors
Discussion
Loading...
Member takes
Implication
Does not support clinical adoption of FXI inhibitors; leaves open confirmation of net benefit in phase III trials.
Structured PICO
Do factor XI inhibitors prevent thrombosis while minimizing bleeding risks in patients at risk of thrombotic events?
P
Population
Patients at risk of thrombosis, including those with venous thrombosis, arterial thromboembolism, end-stage renal disease, mechanical devices, thrombotic antiphospholipid syndrome, or sickle cell disease
I
Intervention
Factor XI (FXI) inhibitors
O
Outcome
Thrombosis prevention and bleeding risk reduction
Factor XI inhibition represents a promising new anticoagulant strategy that may decouple thrombosis prevention from bleeding risk, particularly in high-risk populations.
Cite This Study
Lee et al. (2024) studied this question.